Zobrazeno 1 - 10
of 110
pro vyhledávání: '"Eitan, Kerem"'
Autor:
Micha Aviram, Huda Mussaffi, Elie Picard, Eitan Kerem, Drorith Hochner Celnikier, Bar Gindi Reiss, Javier Miranda, Hannah Blau, Noah Lechtzin, Hagai Amsalem, Joel Melo, Michal Shteinberg, Gema Pérez, Inbal Golan Tripto, Stefano Aliberti, Hagit Levine, Malena Cohen-Cymberknoh, Michal Gur, Joel Reiter, Lea Bentur, Galit Livnat, Francesco Blasi, Eva Polverino, Michal Novoselsky
Publikováno v:
Journal of Cystic Fibrosis. 20:388-394
Background With increasing longevity and quality of life in adults with Cystic fibrosis (CF), growing maternity rates are reported. Women with severe CF are becoming pregnant, with unpredictable maternal and fetal outcomes. Aim To determine how basel
Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations
Autor:
Daniel Campbell, Caroline A. Owen, H. Ellemunter, Neil Ahluwalia, Linda T Wang, Claire E. Wainwright, Anne Munck, Eitan Kerem
Publikováno v:
Journal of Cystic Fibrosis
Journal of Cystic Fibrosis, Elsevier, 2020, 19, pp.962-968. ⟨10.1016/j.jcf.2020.04.015⟩
Journal of Cystic Fibrosis, Elsevier, 2020, 19, pp.962-968. ⟨10.1016/j.jcf.2020.04.015⟩
Background Tezacaftor/ivacaftor is a CFTR modulator approved to treat people with cystic fibrosis (pwCF) who are homozygous (F/F) or heterozygous for the F508del-CFTR mutation and a residual function mutation (F/RF). This randomized, double-blind, pl
Autor:
Basil Elnazir, Wu Zhong, Gang Liu, Rosemary S.C. Horne, Yu Hong Zhao, Rong Jun Lin, Genesis C. Rivera, Qiang Qin, Anne Eng Neo Goh, Lanny J. Rosenwasser, Bao Ping Xu, Cheng Song Zhao, Yu Guan, Zheng De Xie, Varinder Singh, T. Bernard Kinane, Chun Mei Zhu, Anne B. Chang, Leyla Namazova-Baranova, Su yun Qian, Lu Zhao Feng, Ruth A. Etzel, Hilary Hoey, Rina Triasih, Zhuang Wei, Kazunobu Ouchi, Ling Cao, Yong Hong Yang, Gen Lu, Eitan Kerem, Spencer S. Li, Lance Rodewald, Yue Jie Zheng, Kun Ling Shen, Gary Wing Kin Wong, Christopher O'Callaghan, Jim Buttery
Publikováno v:
World Journal of Pediatrics
Autor:
Patrick A Flume, Reta Fischer Biner, Damian G Downey, Cynthia Brown, Manu Jain, Rainald Fischer, Kris De Boeck, Gregory S Sawicki, Philip Chang, Hildegarde Paz-Diaz, Jaime L Rubin, Yoojung Yang, Xingdi Hu, David J Pasta, Stefanie J Millar, Daniel Campbell, Xin Wang, Neil Ahluwalia, Caroline A Owen, Claire E Wainwright, Ronald L. Gibson, Steven M. Rowe, Noah Lechtzin, Richard C. Ahrens, Karen S. McCoy, Moira Aitken, Scott H. Donaldson, Kimberly Ann McBennett, Joseph M. Pilewski, Joanne Billings, Carlos Milla, Ronald Rubenstein, Daniel Brian Rosenbluth, Rachel Linnemann, Michael R. Powers, Christopher Fortner, Carla Anne Frederick, Theodore G. Liou, Philip Black, Janice Wang, John L. Colombo, Maria Berdella, Maria Veronica Indihar, Cynthia D. Brown, Michael Anstead, Lara Bilodeau, Leonard Sicilian, James Jerome Tolle, Kathryn Moffett, Samya Nasr, Jennifer Taylor-Cousar, Tara Lynn Barto, Nicholas Antos, John S. Rogers, Bryon Quick, Henry R. Thompson, Gregory Sawicki, Bruce Barnett, Robert L. Zanni, Thomas C. Smith, Karen D. Schultz, Claire Keating, Patrick Flume, Gregory J. Omlor, Alix Ashare, Karen Voter, Nighat Mehdi, Maria Gabriela Tupayachi Ortiz, Tonia E. Gardner, Steven R. Boas, Barbara Messore, Edith Zemanick, Raksha Jain, Michael McCarthy, Dana G. Kissner, Kapilkumar Patel, John McNamara, Julie Philley, Ariel Berlinski, Francisco J. Calimano, Terry Chin, Douglas Conrad, Cori Daines, Hengameh H. Raissy, Thomas G. Keens, Jorge E. Lascano, Bennie McWilliams, Brian Morrissey, Santiago Reyes, Subramanyam Chittivelu, Sabiha Hussain, Arvey Stone, James Wallace, Ross Klingsberg, Julie A. Biller, Stephanie Bui, Olaf Sommerburg, Elisabetta Bignamini, Mirella Collura, Alexander Moller, Donatello Salvatore, Chantal Belleguic, Lea Bentur, Ori Efrati, Eitan Kerem, Dario Prais, Esther Quintana Gallego, Peter Barry, Galit Livnat-Levanon, Jose Ramon Villa Asensi, David Stuart Armstrong, Oscar Asensio de la Cruz, Francis Gilchrist, Diana Elizabeth Tullis, Bradley Quon, Larry C. Lands, Nancy Morrison, Annick Lavoie, Barry Linnane, Okan Elidemir, Felix Ringshausen, Matthias Kappler, Helge Hebestreit, Jochen Mainz, Alexander Kiefer, Cordula Koerner-Rettberg, Doris Staab, Wolfgang Gleiber, Tacjana Pressler, Florian Stehling, Andreas Hector, Sivagurunathan Sutharsan, Lutz Naehrlich, Damian Downey, Jane Carolyn Davies, Robert Ian Ketchell, Mary Patricia Carroll, Simon Doe, Gordon MacGregor, Edward Fairbairn Nash, Nicholas Withers, Daniel Gavin Peckham, Martin James Ledson, Sonal Kansra, Timothy William Rayner Lee, Bertrand Delaisi, Gilles Rault, Jean Le Bihan, Dominique Hubert, Isabelle Fajac, Isabelle Sermet-Gaudelus, Marleen Bakker, Bert Arets, Christiane De Boeck, Raphael Chiron, Philippe Reix, Catherine Mainguy, Eva van Braeckel, Anne Malfroot, Isabelle Durieu, Nadine Desmazes Dufeu, Anne Prevotat, Renske van der Meer, Petrus Merkus, E.J.M. Weersink, Isabel Barrio Gomez-Aguero, Silvia Gartner, Amparo Sole Jover, Antonio Alvarez Fernandez, Desmond William Cox, Edward F. McKone, Barry James Plant, Hiranjan Selvadurai, Simon David Bowler, Claire Elizabeth Wainwright, Daniel Smith, Peter Gordon Middleton, John William Wilson, Sonia Volpi, Carla Colombo, Benedetta Fabrizzi, Vincenzina Lucidi, Federico Cresta, Salvatore Cucchiara, Ernst Eber, Helmut Ellemunter, Isidor Huttegger, Lena Hjelte, Christina Krantz, Marita Gilljam
Publikováno v:
lancet. Respiratory medicine, 9(7), 733-746. Elsevier Limited
VX14-661-110 study group 2021, ' Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study ', The Lancet Respiratory Medicine . https://doi.org/10.1016/S2213-2600(20)30510-5
VX14-661-110 study group 2021, ' Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study ', The Lancet Respiratory Medicine . https://doi.org/10.1016/S2213-2600(20)30510-5
Summary Background Tezacaftor–ivacaftor is an approved cystic fibrosis transmembrane conductance regulator (CFTR) modulator shown to be efficacious and generally safe and well tolerated over 8–24 weeks in phase 3 clinical studies in participants
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf49af3de3f90b3a65bf102dbba3756b
https://pure.amc.nl/en/publications/longterm-safety-and-efficacy-of-tezacaftorivacaftor-in-individuals-with-cystic-fibrosis-aged-12-years-or-older-who-are-homozygous-or-heterozygous-for-phe508del-cftr-extend-an-openlabel-extension-study(cc1b629c-44f6-4a77-aff2-ea80f4598819).html
https://pure.amc.nl/en/publications/longterm-safety-and-efficacy-of-tezacaftorivacaftor-in-individuals-with-cystic-fibrosis-aged-12-years-or-older-who-are-homozygous-or-heterozygous-for-phe508del-cftr-extend-an-openlabel-extension-study(cc1b629c-44f6-4a77-aff2-ea80f4598819).html
Publikováno v:
Respiratory Medicine. 151:96-101
Background Cystic fibrosis (CF) and primary ciliary dyskinesia (PCD) are characterized by impaired mucociliary clearance causing sinopulmonary infections and airway inflammation. However, they differ in many aspects including multisystemic involvemen
Autor:
Malena Cohen-Cymberknoh, Itai Gross, Eitan Kerem, Joel Reiter, Alex Gileles-Hillel, Avigdor Hevroni, Ira Erlichman, David Shoseyov, Reuven Tsabari, Oren Gordon
Publikováno v:
Pediatric Pulmonology. 54:901-906
Rationale Necrotizing pneumonia is characterized by destruction and liquefaction of the lung tissue and loss of the normal pulmonary parenchymal architecture. During the course of resolution areas of hyperlucency are formed, sometimes with the develo
Autor:
S. Armoni, Yasmeen Abu-Fraiha, Eitan Kerem, Malena Cohen-Cymberknoh, Michael Wilschanski, David Shoseyov, H. Elyashar-Earon
Publikováno v:
Journal of Pediatric Gastroenterology & Nutrition. 68:110-115
In 2012, The North American Cystic Fibrosis Foundation (NACFF) published new guidelines for the treatment of vitamin D deficiency in individuals with cystic fibrosis (CF).The objectives of our study were to assess the efficacy of these guidelines, an
Autor:
Oded Breuer, Roopesh Singh Gangwar, Ahlam Barhoum, Francesca Levi-Schaffer, Eitan Kerem, Mansour Seaf
Publikováno v:
Journal of Immunology Research
Journal of Immunology Research, Vol 2018 (2018)
Journal of Immunology Research, Vol 2018 (2018)
CD48 is a costimulatory receptor associated with human asthma. We aimed to assess the significance of the soluble form of CD48 (sCD48) in allergic and nonallergic asthma. Volunteer patients completed an asthma and allergy questionnaire, spirometry, m
Autor:
Reuven Tsabari, Oded Breuer, Ronen Bar-Yoseph, Malena Cohen-Cymberknoh, David Shoseyov, Eitan Kerem, Elie Picard, Lea Bentur, Avigdor Hevroni
Publikováno v:
Chest. 160(4)
Background Infant pulmonary function tests (iPFTs) in subjects with neuroendocrine cell hyperplasia of infancy (NEHI) have demonstrated significant expiratory airflow obstruction and air trapping. Research question Can indexes from iPFTs be used in t
Autor:
K. De Boeck, Steven M. Rowe, Y. Sun, Michael W. Konstan, J. Mcintosh, Emily DiMango, Eitan Kerem, Paola Melotti, Isabelle Sermet-Gaudelus, Michael Wilschanski
Publikováno v:
J Cyst Fibros
Background Ataluren was developed for potential treatment of nonsense-mutation cystic fibrosis (CF). A previous phase 3 ataluren study failed to meet its primary efficacy endpoint, but post-hoc analyses suggested that aminoglycosides may have interfe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::013093a2ff488ed9d7e77d97f32d4382
https://europepmc.org/articles/PMC9167581/
https://europepmc.org/articles/PMC9167581/